Optiderma Biosciences

Optiderma is a Swiss biotechnology company specializing in the development of innovative topical therapies for lymphatic and skin-related disorders. A spin-off from ETH Zurich, the company utilizes a proprietary platform focused on pro-lymphangiogenic signaling to restore lymphatic vessel function and reduce tissue inflammation. Their lead program, OPT-001, is a topical treatment targeting the Vascular endothelial growth factor receptor 3 (VEGFR-3) to address secondary lymphedema, a condition with significant unmet medical needs. Beyond lymphedema, Optiderma is exploring applications in chronic wound healing and inflammatory skin conditions such as psoriasis. The company's mission is to provide effective, non-invasive therapeutic options for patients suffering from debilitating lymphatic dysfunction and chronic skin diseases.